



ABN: 97 084 464 193

Suite 1 A, Level 2  
802 Pacific Highway  
Gordon NSW 2072

P: +61 2 9844 5422  
F: +61 2 9844 5445



**Australian Securities Exchange Limited  
Companies Announcements Office  
SYDNEY**

**28 May, 2012**

## **On Track To Report Clinical Trial Results In June**

**SYDNEY Australia 28th May 2012:** Bioxyne Limited (ASX: BXN), today confirmed it is on track for the release of data from its Phase IIb trial as scheduled in June.

The Company confirmed the 320-patient study to evaluate the efficacy and safety of the Bioxyne's HI-164OV therapy for patients with chronic obstructive pulmonary disease (COPD) had been closed and that data was in the late stages of analysis.

The primary aim of the study is to assess the impact of treatment with HI-164OV in reducing severe exacerbations in COPD patients and reducing the need for admission to hospital.

There are a number of measures of disease severity being examined which will define the profile and benefits of HI-164OV and its potential long term value.

Bioxyne Chief Executive Officer David Radford said, "We are focused on ensuring accurate communication of the trial results and to also guard against partial and incomplete reporting of the results.

"Given the importance of the results, Bioxyne may consider a short-term trading halt during the period between our receipt of initial data through until the time when the Company has formally assessed the final result and is able to accurately communicate these results to the market.

The primary endpoint in the trial is a demonstration of a reduction in exacerbations requiring oral corticosteroid treatment or hospitalisation.

The secondary endpoints seek to determine if HI-164OV can reduce the severity of exacerbations, the number of patients experiencing exacerbations requiring corticosteroid



ABN: 97 084 464 193

Suite 1 A, Level 2  
802 Pacific Highway  
Gordon NSW 2072

P: +61 2 9844 5422  
F: +61 2 9844 5445



treatment or hospitalisation and a reduction in the use of antibiotics and or corticosteroids.

There have been no indications of patient related safety issues during the trial.

David Radford  
Managing Director

**For Further information please contact:**

At the Company	Media contacts
David Radford Chief Executive Officer Tel: : +61 (0) 407- 218-922 Email: info@bioxyne.com	College Hill Sue Charles – (UK) +44 (0)7968 726585 (AUS) +61 (0)466 924218 Gemma Howe – (UK) +44 (0)20 7866 7860  Email: bioxyne@collegehill.com  City Public Relations Tim Allerton or Andrew Geddes (AUS) +(02) 9267 4511

**About Bioxyne**

Bioxyne Limited (ASX:BNE) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company’s lead therapy, HI-164OV is based on the Company’s proprietary technology that uses the application of mucosal immunology to treat common human diseases. HI-164OV, in Phase IIb clinical trials for Chronic Obstructive Pulmonary Disease (COPD), works by controlling bacterial infections of airways damaged by toxins. The global incidence of COPD, which includes common diseases like bronchitis and emphysema, is growing rapidly and is a substantial burden on health budgets. The results of the Phase IIb clinical study into the safety and efficacy of HI-164OV are expected mid 2012. Bioxyne also makes and sells consumer food supplements, based on a proprietary probiotic compound, generating a source of revenues. For further information please visit **www.bioxyne.com**